March 24, 2025 8:04am

Valuation matters, cell and gene therapy sector equities stocks can be great bargains

Certainty seems less jaded from ever changing signals due tariff fears

News: Verve Therapeutics (VERV +$0.06 pre-open) clearance of its IND application by the FDA for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C).

Pre-open Indications: 1 Sell into Strength, and 6 Positive

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: pumped-up by covering and a barely positive sector close … https://www.regmedinvestors.com/articles/13850

 

Monday: The pre-open Dow futures are UP +0.90% or (+381 points), the S&P futures are UP +1.17% or (+66 points) and the Nasdaq futures are UP +1.43% or (+285 points)

  • Futures jumped Monday on reports President Trump was planning on holding back some of the tariffs initially planned for April 2,
  • European markets opened higher,
  • Asia-Pacific markets are mostly higher, 3/24.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed UP +32.03 points or +0.08%, the S&P closed UP +4.67 points or +0.08% while the Nasdaq closed UP +92.43 points or +0.52%.

Last week, the Dow posted a 1.2% gain, &P 500 posted a 0.5% advance, and the Nasdaq rose 0.2%.

 

Q1/25:  March sessions with 8 positive and 8 negative closes

  • February – 1 holiday, 11 negative and 8 positive closes
  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

  • A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Pre-open:

Sell into Strength:

Alnylam Pharmaceuticals (ALNY) closed up +$29.80 after Thursday’s +$0.10 with a positive +$2.79 or +0.98%

 

Positive Indications:

Beam Therapeutics (BEAM) closed up +$0.43 after Thursday’s -0.77 with a positive +$0.70 or +3%

Blueprint Medicine (BPMC) closed up +$o,25 with a positive +$2.00 or +2.25%

CRISPR Therapeutics (CRSP) closed up =$0.05 after Thursday’s -$0.77 with a positive +$0.83 or +2.01%

Editas Medicine (EDIT) closed down -$0.06 with a positive +$0.08 or +6.11%

Mesoblast (MESO0 closed up +$0.26 with a positive +$1.06or +7.60%

Moderna (MRNA) closed up +$0.21 with a positive +0.30or +0.92%

 

 

The BOTTOM LINE: the last full week, the 4th of March with a 1 session spill over until April …

  • As I have written, “uncle algo and his trading dwarfs” will determine the heights or lows of share pricing”

March to date:

  • 3/21 – Friday closed positive with 17 positive, 16 negative and 2 flats
  • 3/20 – Thursday closed negative with 10 positive, 23 negative and 2 flats
  • 3/19 - Wednesday closed positive with 25 positive, 8 negative and 2 flats
  • 3/18 - Tuesday closed negative with 7 positive, 27 negative and 1 flat
  • 3/17 – Monday closed positive with 24 positive, 10 negative and 1 flat
  • 3/14 – Friday closed positive with 20 positive, 13 negative and 2 flats
  • 3/13 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 3/12 – Wednesday closed positive with 25 positive, 9 negative and1 flat
  • 3/11 - Tuesday closed positive with 23 positive, 11 negative and 1 flat
  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 – Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3/4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

 

Reiterating, “I think it's important just to take a step back, focus on the fundamentals, be selective. I mean, this has definitely been a “sucky” January and February from a stock-picker standpoint given the up/downs. And so, I am relatively neutral across today/Friday’s equity strategy.

  • Reiterating, “Take the emotion out of the sector, think of the reality of the “plays” that exist of who’s really buying.”

It’s all but OVER … earnings season “sparked” a quarterly life crisis…

  • Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject.

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.